Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls

HIV Clinical Trials

Volumn 14, Issue 4, 2013, Pages 175-181

  Bickel, Markus ^a   Lassmann, Christin ^a   Wieters, Imke ^a   Doerr, Hans ^a   Herrmann, Eva ^a   Wicker, Sabine ^a   Brodt, Hans ^a   Stephan, Christoph ^a   Allwinn, Regina ^a   Jung, Oliver ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

adjuvanted; H1N1; hemagglutination inhibition assay; HIV; memory response; trivalent influenza vaccine; vitamin D

Indexed keywords

2010 11 TRIVALENT; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLUENZA A; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEASONAL INFLUENZA; SEROCONVERSION; SINGLE DRUG DOSE; WINTER;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIBODIES, VIRAL; FEMALE; HIV-1; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED;

EID: 84881417843     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1404-175     Document Type: Article

References (26)

1. Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of a monovalent 2009 infl uenza A (H1N1) vaccine in an immunocompromised population: A prospective study comparing HIV-infected adults with HIV uninfected adults. Clin Infect Dis. 2011; 52:138-146.
2. Launay O, Desaint C, Durier C, et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1 v vaccine adjuvanted with AS03A or unadjuvanted in HIVinfected adults: A randomized, controlled trial. J Infect Dis. 2011; 204:124-134.
3. Tebas P, Frank I, Lewis M, et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS. 2010; 24:2187-2192.
4. Yanagisawa N, Maeda K, Ajisawa A, et al. Reduced immune response to infl uenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects. Vaccine. 2011; 29: 5697-5698.
5. Tremblay CL, Rouleau D, Fortin C, et al. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 infl uenza vaccine, in HIV-1-infected patients. Vaccine. 2011; 29:1359-1363.
6. Bickel M, Wieters I, Khaykin P, et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS. 2010; 24:F31-F5.
7. Cooper C, Klein M, Walmsley S, et al. High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults. HIV Clin Trials. 2012; 13(1):23-32.
8. Fabbiani M, Di Giambenedetto S, Sali M, et al. Immune response to influenza A (H1N1)v monovalent MF59- adjuvanted vaccine in HIV-infected patients. Vaccine. 2011; 29:2836-2839.
9. Kajaste-Rudnitski A, Galli L, Nozza S, et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v infl uenza vaccine in HIV-1-infected individuals. AIDS. 2011; 25:177-183.
10. Manuel O, Pascual M, Hoschler K, et al. Humoral response to the infl uenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis. 2011; 52:248-256.
11. Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP. Response to 2009 pandemic infl uenza A (H1N1) vaccine in HIV-infected patients and the infl uence of prior seasonal infl uenza vaccination. PLoS One. 2011; 6:e16496.
12. Tremblay CL, Rouleau D, Fortin C, et al. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 infl uenza vaccine, in HIV-1-infected patients. Vaccine. 2011; 29:1359-1363.
13. Cooper CL. Pandemic H1N1 2009 infl uenza and HIV: A review of natural history, management and vaccine immunogenicity. Curr Opin Infect Dis. 2012; 25(1):26-35.
14. Peters PJ, Skarbinski J, Louie JK, et al. HIV-infected hospitalized patients with 2009 pandemic influenza A (pH1N1): United States, spring and summer 2009. Clin Infect Dis. 2011; 52(Suppl 1):S183-188.
15. Ormsby CE, de la Rosa-Zamboni D, Vazquez-Perez J, et al. Severe 2009 pandemic infl uenza A (H1N1) infection and increased mortality in patients with late and advanced HIV disease. AIDS. 2010; 25:435-439.
16. Bickel M, von Hentig N, Wieters I, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 infl uenza A vaccine in HIV-1-infected patients. Clin Infect Dis. 2011; 52(1):122-127.
17. Crum-Cianflone NF, Iverson E, Defang G, et al. Durability of antibody responses after receipt of the monovalent 2009 pandemic infl uenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. Vaccine. 2011; 29:3183-3191.
18. Chadha MK, Fakih M, Muindi J, et al. Effect of 25-hydroxyvitamin D status on serological response to infl uenza vaccine in prostate cancer patients. Prostate. 2011; 71(4):368-372. doi: 10.1002/pros.21250. 19
19. doi: 10.1002/pros.21250. 19. Mueller NJ, Fux CA, Ledergerber B, et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010; 24(8):1127-1134.
20. Allwinn R, Geiler J, Berger A, Cinatl J, Doerr HW. Determination of serum antibodies against swine-origin infl uenza A virus H1N1/09 by immunofl uorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans? Med Microbiol Immunol. 2010; 199:117-121.
21. WHO. World Health Organisation manual on animal infl uenza diagnosis and surveillance. 2009. WHO/CDS/CSR/ NCS/2002.5. http://www.who.int/vaccine- research/diseases/influenza/WHO-manual-on-animal-diagnosis-and-surveillance- 2002-5.pdf. Accessed August 17, 2012.
22. US Food and Drug Administration. Guidance for industry: Clinical data needed to support the licensure of pandemic influenza vaccines. 2007. http://www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf. Accessed August 17, 2012.
23. Siegrist CA, van Delden C, Bel M, et al. Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine. PLoS One. 2012; 7(7):e40428.
24. Walker WT, de Whalley P, Andrews N, et al. H1N1 Antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal infl uenza vaccine: A multicenter follow-on study. Clin Infect Dis. 2012; 54(5):661-669.
25. Kikuchi T, Iwatsuki-Horimoto K, Adachi E, et al. Improved neutralizing antibody response in the second season after a single dose of pandemic (H1N1) 2009 infl uenza vaccine in HIV-1-positive adults [published online ahead of print April 10, 2012]. Vaccine. 2012; 30(26):3819-3823.
26. Cooper C, Thorne A; Canadian HIV Trials Network Ctn Influenza Vaccine Research Group. Vitamin D supplementation does not increase immunogenicity of seasonal infl uenza vaccine in HIV-infected adults. HIV Clin Trials. 2011; 12(5):275-276.